0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Sulfobromophthalein-Glutathione Conjugating Enzyme During Mammalian Development

J. Krasner, PhD; S. J. Yaffe, MD
Am J Dis Child. 1968;115(2):267-272. doi:10.1001/archpedi.1968.02100010269017.
Text Size: A A A
Published online

THE HAZARDS of drugs prescribed to newborn infants on the basis of information obtained in adults has emphasized the need for pharmacologic studies during this critical stage of development. Since alterations in metabolism have usually been responsible for the increased (drug) toxicity noted in the neonatal period, we have undertaken a systematic assay of these processes during postnatal development. Efforts have been concentrated on conjugation mechanisms in which a chemical moiety is coupled to the drug substrate, resulting in an increased water solubility of the conjugate and enhanced excretion. Glutathione (GSH) coupling to sulfobromophthalein is an example of this type of reaction.

Many studies have demonstrated that sulfobromophthalein (Bromsulphalein, BSP) is inadequately removed from the blood of full-term1,2 and premature infants3,4 during the neonatal period. Bromsulphalein concentrations decrease to adult values in the human infant at 3 to 4 weeks of age and appear to be related to

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();